

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 60787

Manuscript Type: CASE REPORT

Complete pathological response in locally advanced non-small-cell lung cancer patient: A case report

Hypofractionation in LA-NSCLC

Abstract

BACKGROUND

Chemotherapy and radiotherapy followed by durvalumab is currently the standard treatment for locally advanced node-positive non-small-cell lung cancer (NSCLC). We describe the case of a patient with locally advanced node-positive LA- NSCLC treated in a phase II prospective protocol with chemotherapy, accelerated hypofractionated radiotherapy (AHRT) and surgery in the pre-immunotherapy era.

CASE SUMMARY

Match Overview

1	Internet 70 words crawled on 22-Jan-2020 ro-journal.biomedcentral.com	4%
2	Internet 16 words crawled on 21-Feb-2020 link.springer.com	1%
3	Internet 16 words s3-eu-west-1.amazonaws.com	1%
4	Internet 14 words crawled on 03-Apr-2021 doaj.org	1%

Complete pathological response in LA-NSCLC patient: case report c



ALL

IMAGES

VIDEOS

723,000 Results

Any time ▼

Pathological complete response after preoperative ...

<https://www.ncbi.nlm.nih.gov/pubmed/31476559>

This **case report** presents the apparent effectiveness of preoperative FOLFOX plus bevacizumab as shown by **pathological complete response** (pCR). Additionally, we **review** the relevant **literature** and discuss the clinical management of locally advanced rectal cancer with preoperative chemotherapy.

Cited by: 1

Author: Ryoichi Miyamoto, Kazunori Kikuchi, Atsus...

Publish Year: 2019

Pathological complete response with anti-PD-1 therapy in a ...

<https://pubmed.ncbi.nlm.nih.gov/27355330>

Observations: We **report** the first **case** of MSI-high, BRAF mutant metastatic CRC that had an excellent **response** (**pathologic complete response**) to anti-PD-1 therapy. We take this opportunity to **review** the similar cases in **literature** and discuss combined MMR and ...

Cited by: 14

Author: Amikar Sehdev, Harvey M Cramer, Ashley A...

Publish Year: 2016

Cancers | Free Full-Text | Prognostic Factors and Long ...

<https://www.mdpi.com/2072-6694/12/12/3572/htm> ▼

Thus, **LA-NSCLC patients** with **pathological complete response** (pCR) are therefore optimal candidates to undergo surgery after IT, achieving good to very good long-term survival [9,10,11]. However, this specific subset of **patients** is highly selective and only 10–30% of **LA-NSCLC patients** present with pCR after IT according to **literature** data [9 ...

Author: Filippo Lococo, Carolina Sassorossi, Da...

Publish Year: 2020

Complete response to thalidomide and dexamethasone in a ...

ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

TOOLS ▾

A pathological complete response to neoadjuvant ...

<https://pubmed.ncbi.nlm.nih.gov/33209635>

Abstract. **Lung cancer** is the leading cause of **cancer**-related mortality worldwide. **Patients** with **locally advanced non-small cell lung cancer** (NSCLC) have lower overall survival. Studies have shown that some **patients** with unresectable stage III NSCLC develop disease progression after initial chemoradiotherapy, and new treatment is needed to improve the prognosis of these **patients**.

Author: Pengqiang Gao, Hao Chen, Taidui Zeng,... **Publish Year:** 2020

[PDF] 2160 Case Report A pathological complete response to ...

<https://tocr.amegroups.com/article/download/44422/pdf>

In conclusion, this case report showed an advanced NSCLC **patient** who achieved **complete pathological response** after short-term neoadjuvant combination therapy, although long-term follow-up is still needed to fully support the rationale of the curative strategy. We believe that immunotherapy combined with chemotherapy has the

A pathological complete response to neoadjuvant ...

<https://tocr.amegroups.com/article/view/44422/html> ▾

In conclusion, this case report showed an **advanced NSCLC patient** who achieved **complete pathological response** after **short-term neoadjuvant combination therapy**, although long-term follow-up is still needed to fully support the rationale of the curative strategy.

Author: Pengqiang Gao, Hao Chen, Taidui Zeng,... **Publish Year:** 2020

Complete pathological response in NSCLCs

[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(13\)70334-6](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70334-6)

Improvements in outcomes for **patients** with resectable **lung** cancers have plateaued. Clinical trials of resectable non-small-cell **lung** cancers with overall survival as the primary endpoint require a decade or longer to **complete**, are expensive, and limit innovation. A surrogate for survival, such as **pathological response** to neoadjuvant chemotherapy, has the potential to improve the efficiency of ...

Cited by: 176 **Author:** Matthew D Hellmann, Jamie E Chaft, Willia...

Publish Year: 2014

Complete Pathologic Response in Lung Tumors in Two ...

<https://www.sciencedirect.com/science/article/pii/S1556086415322607>

Nov 01, 2011 · **Patients** with non-small cell **lung cancer** with a sensitizing mutation in the epidermal growth factor receptor (EGFR) are likely to respond to treatment with an EGFR inhibitor. In some **patients**